News | February 18, 2022
Ligand posts strong 2021 performance
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Share of government health expenditure in total health expenditure increases to 40.8% (2017-18) from 28.6% (2013-14)
After a volatile decade in which approvals swung sharply from year to year, 2025’s total pushed past long-term norms, exceeding the 10-year average
M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
Health Ministry reviews progress, highlights targeted interventions in high-burden states, and calls for stronger surveillance and stigma reduction to achieve a leprosy-free India
Community healthcare initiatives reach a milestone year, with services spanning 90 districts, 22 states, and over 70 lakh cumulative beneficiaries since 2006
The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases
At the center of the project is a new cosmetics line developed through collaboration between industry and medicine
The accepted studies span several critical areas of oncology, including nutrition, genomics, precision medicine, patient-reported outcomes, and community-based cancer care
First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
